An Unbiased High‐Throughput Drug Screen Reveals a Potential Therapeutic Vulnerability in the Most Lethal Molecular Subtype of Pancreatic Cancer

In multiple in vitro and in vivo models of pancreatic ductal adenocarcinoma (PDAC), spanning human and murine PDAC cells, and orthotopic xenografts, researchers determined that the expression of keratin 17 resulted in a more than two‐fold increase in resistance to Gem and 5‐fluorouracil, key components of current standard‐of‐care chemotherapeutic regimens.
[Molecular Oncology]
[zotpress items='{1254621:2LFVAMRX}’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Glutathione S-Transferase pi-1 Knockdown Reduces Pancreatic Ductal Adenocarcinoma Growth by Activating Oxidative Stress Response Pathways

Researchers showed glutathione S-transferase pi-1 knockdown reduced pancreatic ductal adenocarcinoma (PDAC) cell growth, prolonged the G0/G1 phase, and elevated reactive oxygen species in PDAC cells.
[Cancers]
[zotpress items='{1254621:49ZKRAMV}’ style=’apa’ cite=’yes’]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Plasma Interleukin-8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

In vivo activity of nanoliposomal irinotecan was validated in an orthotopic nude murine model expressing TAK1-specific shRNA. Differential expression profiling revealed the gene coding for interleukin-8 as the most significantly downregulated in shTAK1 pancreatic cancer cell lines.
[Clinical Cancer Research]
[zotpress items='{1254621:42HSG9CX}’ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share

Seven Bridges and the Pancreatic Cancer Action Network Partner to Develop High-Quality, Actionable Cancer Data Platform

Seven Bridges announced that it has been selected by the Pancreatic Cancer Action Network to build a customized, integrated health data platform to accelerate pancreatic cancer research.
Abstract
Bookmark

No account yet? Register

Share

PharmaCyte Biotech Completes Final cGMP Audit of Manufacturing Facility for Pancreatic Cancer Clinical Trial Product

PharmaCyte Biotech, Inc. announced that cGMP Validation, the company’s cGMP consultant, has completed its post manufacturing audit of the manufacturing facility in Thailand and that the facility has successfully passed the audit.
Full Article
Bookmark

No account yet? Register

Share

Huge Open-Access Journal Deal Inked by University of California and Springer Nature

The University of California (UC) system announced it has signed the biggest open-access deal in North America with one of the largest commercial scientific publishers. The agreement with Springer Nature includes a commitment by the publisher to explore making all articles that UC corresponding authors publish in the Nature family of journals immediately free to read on publication starting in 2022.
[ScienceInsider]
Editorial
Bookmark

No account yet? Register

Share

BAP1 Is a Haploinsufficient Tumor Suppressor Linking Chronic Pancreatitis to Pancreatic Cancer in Mice

Researchers found that heterozygous loss of histone H2A lysine 119 deubiquitinase BRCA1 Associated Protein-1 associates with a history of chronic pancreatitis and occurs in 25% of pancreatic ductal adenocarcinomas and 40% of acinar cell carcinomas.
[Nature Communications]
[zotpress items='{1254621:VLCSLFLD}’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Mir34a Constrains Pancreatic Carcinogenesis

Investigators showed that the accelerated phenotype is driven by an early up-regulation of the pro-inflammatory cytokines TNFA and IL6 in normal acinar cells and accompanied by the recruitment of immune cells.
[Scientific Reports]
[zotpress items='{1254621:FY72ASEF}’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Targeting Focal Adhesion Kinase in Cancer Cells and the Tumor Microenvironment

Scientists discuss the role of nuclear focal adhesion kinase (FAK) as a driver for tumor cell survival as well as potential therapeutic strategies to target FAK in both tumors and the tumor microenvironment
[Experimental and Molecular Medicine]
[zotpress items='{6445212:LPIMZ9DW}’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Pre-Clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes

Two TYK2 inhibitors provided by Nimbus Lakshmi Inc, were tested in human insulin-producing EndoC-βH1 cells and human islets to evaluate their effect on interferon-α signaling and beta cell function.
[Diabetes Obesity & Metabolism]
[zotpress items='{6445218:ZIYKHMCL}’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Electrogenetic Cellular Insulin Release for Real-Time Glycemic Control in Type 1 Diabetic Mice

Focusing on type 1 diabetes, scientists engineered electrosensitive human β cells (Electroβ cells). Wireless electrical stimulation of Electroβ cells inside a custom-built bioelectronic device provided real-time control of vesicular insulin release.
[Science]
[zotpress items='{6445218:FBL6P9PQ}’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share